Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jan 11, 2021 9:30am
205 Views
Post# 32265908

RE:Not a good sign

RE:Not a good sign
Forestview wrote: When both Marky and Mugsy are disappointed.  :(

But, maybe 3B has a point.  Nothing has changed with the science.  What we got here were soe vague details and some delays (which are covid driven).  If the FDA application happens in a matter of weeks, let's say end of Feb, and it's approved by early Q2 (is that possible?) then we should see a spike.  In the end, the IP is sound.  We all know that.  Nothing's changed there.

I do wonder though if we will have see buy outs in the billions.  I may need to temper my expectations and re work my retirement model to something more realistic.  Dan doesn't seem to be aggressive from that perspective.  

Stay long.  I've been in this for two years, and doubled my position over the last six months.  I'm not selling, I'm just going to be less optimistic.


Well ... the partnering is still on track ... from what I can see.  That's the wild card.  Anything can happen here.

We have some delay which shouldn't be a surprise but it isn't ideal for the product plan (OTENA).

More questions than answers if you've been here a while ... that's all ... hahaha ... 
<< Previous
Bullboard Posts
Next >>